Jenna Cohen | executive |
Kathryn Haviland | executive |
Philina Lee | executive |
Fouad Namouni | executive |
Michael Landsittel | executive |
Bradley Canino | analyst |
Dane Leone | analyst |
Reni Benjamin | analyst |
Eun Yang | analyst |
Marc Frahm | analyst |
Salveen Richter | analyst |
Michael Schmidt | analyst |
Ami Fadia | analyst |
Michael Ulz | analyst |
Matthew Biegler | analyst |
Peter Lawson | analyst |
Derek Archila | analyst |
David Lebowitz | analyst |
Joel Beatty | analyst |
Good morning, ladies and gentlemen. My name is Glenn. I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines' Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] I will now turn it to Jenna Cohen, Vice President of Investor Relations to begin.